Novel markers including tumor mutation burden, KRAS mutation status, TP53, tumor-infiltration lymphocytes, and PD-L1 expressions have been demonstrated to exhibit important values of clinical responses in treatments based on immune-related methods [11–13]. The gene discussed is KRAS; the disease is neoplasm.